Current Allergy and Asthma Reports

, 6:270

Safety of topical calcineurin inhibitors in atopic dermatitis: Evaluation of the evidence

Authors

  • Jonathan M. Spergel
    • Division of Pediatric Allergy-ImmunologyUniversity of Colorado Health Sciences Center
Article

DOI: 10.1007/s11882-006-0059-7

Cite this article as:
Spergel, J.M. & Leung, D.Y.M. Curr Allergy Asthma Rep (2006) 6: 270. doi:10.1007/s11882-006-0059-7

Abstract

Topical calcineurin inhibitors (pimecrolimus, Elidel, East Hanover, NJ; and tacrolimus, Protopic, Tokyo, Japan) have been approved for the use in atopic dermatitis since the year 2000. These compounds represent a relatively safe class of topical anti-inflammatory, nonsteroidal therapy. However, in January of 2006, the US Food and Drug Administration issued a black box warning on these compounds about possible concerns of increased long-term malignancy risk due to systemic immunosuppression. To date, studies from clinical trials, systemic absorption, and post-marketing surveillance show no evidence for this systemic immunosuppression or increased risk for any malignancy.

Copyright information

© Current Science Inc 2006